At TERMIS-AP 2025 (Tissue Engineering and Regenerative Medicine International Society – Asia Pacific 2025, Wuhan, China, October 16-19, 2025), Dr. Yasuo Miyagi, Associate Professor of Cardiovascular Surgery at Nippon Medical School, spoke about the potential of TamaBio’s PeriBeam® as an innovative treatment (for myocardial infarction) in his lecture (“Design of Biomaterial Technology Indispensable for Regenerative Medicine – Optimal Tissue Engineering Applications for Heart Regeneration -“). Please contact us for more information about the tissue repair properties of our technology (PTFE sheets produced with/by ion irradiation) and its potential to contribute to myocardial repair after myocardial infarction.
TamaBio Company Limited
Head Office : 402 Gran Creste 2-2-18 Sakai Musashino-shi Tokyo 180-0022 Japan
Medical device manufacturing / Class 1 manufacturing and sales Development
Manufacturing, and Distributuon of Class IV highly controlled medical devices
(dura mater and pericardial prosthesis material)
Development, manufacturing, and sales of regenerative medical devices and other synthetic artificial biomembranes
Managing Director / CEO : Tetsuya Nagao
TEL : +81-422-53-5051 / FAX : +81-422-38-5091